About
Jeffrey Chodakewitz, M.D., has served on Adicet Bio's board since the completion of the merger and previously served on the resTORbio board from August 2018.
He was Executive Vice President of Clinical Medicine and External Innovation at Vertex Pharmaceuticals and earlier its Chief Medical Officer and EVP of Global Medicines Development and Medical Affairs. Before Vertex he spent more than two decades at Merck & Co. in roles including Head of Infectious Diseases and Vaccines Global Development. He is a Diplomate of the National Board of Medical Examiners and the American Board of Internal Medicine, and holds a B.S. in Biochemistry and an M.D. from Yale.
Roles
Adicet Bio, Inc.
Director · Current role
2020–present
Vertex Pharmaceuticals Incorporated
EVP, Clinical Medicine & External Innovation · Previously Chief Medical Officer and EVP, Global Medicines Development and Medical Affairs from January 2014 to April 2018, and a member of the Vertex Executive Committee.
2018-2019
Merck & Co., Inc.
Various senior roles, incl. Head of Infectious Diseases and Vaccines Global Development · Held a number of positions over more than two decades, including SVP of Global Scientific Strategy and SVP of Late Stage Development.
1990-2013
Blackstone Life Sciences
Senior/executive advisor
2019-2022
Freeline Therapeutics Holdings plc
Board member
2019-2024
External Roles
Yale University Ventures
Entrepreneur-in-Residence
—
Ascenta Capital Management LLC
Advisory Partner
—
Praxis Precision Medicines, Inc.
Board member
—
Schrodinger, Inc.
Board member
—
Director Compensation
FY 2025Fees earned or paid in cash
$48,530
Stock awards
$4,630
Option awards
$15,715
Total
$68,876
Also at Adicet Bio, Inc.
See how Top Bucket AI works for your firm
Request DemoTop Bucket AI Research
Stay ahead of private markets
Research and market intelligence for private-markets professionals.
✓
You're subscribed.
Thanks for signing up.